Search Results - "GILMAN, Andrew L"

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931 by Ozkaynak, M Fevzi, Gilman, Andrew L, London, Wendy B, Naranjo, Arlene, Diccianni, Mitchell B, Tenney, Sheena C, Smith, Malcolm, Messer, Karen S, Seeger, Robert, Reynolds, C Patrick, Smith, L Mary, Shulkin, Barry L, Parisi, Marguerite, Maris, John M, Park, Julie R, Sondel, Paul M, Yu, Alice L

“…A phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as…”
Get full text

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group by Gilman, Andrew L, Ozkaynak, M Fevzi, Matthay, Katherine K, Krailo, Mark, Yu, Alice L, Gan, Jacek, Sternberg, Adam, Hank, Jacquelyn A, Seeger, Robert, Reaman, Gregory H, Sondel, Paul M

“…Recurrence of high-risk neuroblastoma is common despite multimodality therapy. ch14.18, a chimeric human/murine anti-G(D2) antibody, lyses neuroblastoma cells…”
Get full text

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group by Fujii, Hisaki, Cuvelier, Geoff, She, Kevin, Aslanian, Soudabeh, Shimizu, Hiromi, Kariminia, Amina, Krailo, Mark, Chen, Zhengjia, McMaster, Rob, Bergman, Axel, Goldman, Frederick, Grupp, Stephen A., Wall, Donna A., Gilman, Andrew L., Schultz, Kirk R.

“…Numerous chronic graft-versus-host disease (cGVHD) biomarkers have been identified in limited, single-institution studies without validation. We hypothesized…”
Get full text

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy by Erbe, Amy K, Wang, Wei, Reville, Patrick K, Carmichael, Lakeesha, Kim, KyungMann, Mendonca, Eneida A, Song, Yiqiang, Hank, Jacquelyn A, London, Wendy B, Naranjo, Arlene, Hong, Fangxin, Hogarty, Michael D, Maris, John M, Park, Julie R, Ozkaynak, M F, Miller, Jeffrey S, Gilman, Andrew L, Kahl, Brad, Yu, Alice L, Sondel, Paul M

“…Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function…”
Get full text

Alternative donor hematopoietic stem cell transplantation for sickle cell disease by Gilman, Andrew L., Eckrich, Michael J., Epstein, Stacy, Barnhart, Carrie, Cannon, Mark, Fukes, Tracy, Hyland, Michelle, Shah, Krishna, Grochowski, Darci, Champion, Elizabeth, Ivanova, Anastasia

“…Most patients who could be cured of sickle cell disease (SCD) with stem cell transplantation do not have a matched sibling donor. Successful use of alternative…”
Get full text

Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study by Jacobsohn, David A., Gilman, Andrew L., Rademaker, Alfred, Browning, Brittan, Grimley, Michael, Lehmann, Leslie, Nemecek, Eneida R., Thormann, Kimberly, Schultz, Kirk R., Vogelsang, Georgia B.

“…There is no standard therapy for steroid-refractory chronic graft-versus-host disease (GVHD). This problem is particularly daunting in children with chronic…”
Get full text

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931 by Ozkaynak, M Fevzi, Gilman, Andrew L, London, Wendy B, Naranjo, Arlene, Diccianni, Mitchell B, Tenney, Sheena C, Smith, Malcolm, Messer, Karen S, Seeger, Robert, Reynolds, C Patrick, Smith, L Mary, Shulkin, Barry L, Parisi, Marguerite, Maris, John M, Park, Julie R, Sondel, Paul M, Yu, Alice L

“…[This corrects the article DOI: 10.3389/fimmu.2018.01355.]…”
Get full text

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 by Yu, Alice L, Gilman, Andrew L, Ozkaynak, M Fevzi, Naranjo, Arlene, Diccianni, Mitchell B, Gan, Jacek, Hank, Jacquelyn A, Batova, Ayse, London, Wendy B, Tenney, Sheena C, Smith, Malcolm, Shulkin, Barry L, Parisi, Marguerite, Matthay, Katherine K, Cohn, Susan L, Maris, John M, Bagatell, Rochelle, Park, Julie R, Sondel, Paul M

“…Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for…”
Get full text

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma by Yu, Alice L, Gilman, Andrew L, Ozkaynak, M. Fevzi, London, Wendy B, Kreissman, Susan G, Chen, Helen X, Smith, Malcolm, Anderson, Barry, Villablanca, Judith G, Matthay, Katherine K, Shimada, Hiro, Grupp, Stephan A, Seeger, Robert, Reynolds, C. Patrick, Buxton, Allen, Reisfeld, Ralph A, Gillies, Steven D, Cohn, Susan L, Maris, John M, Sondel, Paul M

“…This study evaluated whether the addition of a monoclonal antibody against the tumor-associated disialoganglioside GD2, in combination with GM-CSF and…”
Get full text

Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group by Desai, Ami V, Gilman, Andrew L, Ozkaynak, Mehmet Fevzi, Naranjo, Arlene, London, Wendy B, Tenney, Sheena C, Diccianni, Mitchell, Hank, Jacquelyn A, Parisi, Marguerite T, Shulkin, Barry L, Smith, Malcolm, Moscow, Jeffrey A, Shimada, Hiroyuki, Matthay, Katherine K, Cohn, Susan L, Maris, John M, Bagatell, Rochelle, Sondel, Paul M, Park, Julie R, Yu, Alice L

“…Postconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2 improved outcomes for patients with…”
Get full text

Diagnosis and Treatment of Chronic Graft-Versus-Host Disease by Gilman, Andrew L., Serody, Jonathan

“…Chronic graft-versus-host disease (GVHD) is the major cause of non-relapse morbidity and mortality after hematopoietic stem cell transplant (HSCT). GVHD also…”
Get full text

Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders by Madden, Lisa M, Hayashi, Robert J, Chan, Ka Wah, Pulsipher, Michael A, Douglas, Dorothea, Hale, Gregory A, Chaudhury, Sonali, Haut, Paul, Kasow, Kimberly A, Gilman, Andrew L, Murray, Lisa M, Shenoy, Shalini

“…Abstract Reduced-intensity conditioning (RIC) before hematopoietic stem cell transplantation (HCT) in children could result in fewer complications during…”
Get full text

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group by Erbe, Amy K, Wang, Wei, Carmichael, Lakeesha, Kim, KyungMann, Mendonça, Eneida A, Song, Yiqiang, Hess, Dustin, Reville, Patrick K, London, Wendy B, Naranjo, Arlene, Hank, Jacquelyn A, Diccianni, Mitchell B, Reisfeld, Ralph A, Gillies, Stephen D, Matthay, Katherine K, Cohn, Susan L, Hogarty, Michael D, Maris, John M, Park, Julie R, Ozkaynak, M Fevzi, Gilman, Andrew L, Yu, Alice L, Sondel, Paul M

“…In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free…”
Get full text

Primary graft failure after umbilical cord blood transplant rescued by parental haplocompatible stem cell transplantation by Dvorak, Christopher C, Gilman, Andrew L, Horn, Biljana, Cowan, Morton J

“…AB Graft failure and aplasia are known complications of umbilical cord blood (UCB) hematopoietic stem cell transplantation (HSCT). In the absence of a second…”
Get full text

Donor lymphocyte infusion and methotrexate for immune recovery after T‐cell depleted haploidentical transplantation by Gilman, Andrew L., Leung, Wing, Cowan, Morton J., Cannon, Mark, Epstein, Stacy, Barnhart, Carrie, Shah, Krishna, Hyland, Michelle, Fukes, Tracy, Ivanova, Anastasia

“…CD34+ cell selection minimizes graft‐versus‐host disease (GVHD) after haploidentical donor stem cell transplant but is associated with slow immune recovery and…”
Get full text

Phase I Study of ch 14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue : A Report From the Children's Oncology Group by GILMAN, Andrew L, FEVZI OZKAYNAK, M, SONDEL, Paul M, MATTHAY, Katherine K, KRAILO, Mark, YU, Alice L, GAN, Jacek, STERNBERG, Adam, HANK, Jacquelyn A, SEEGER, Robert, REAMAN, Gregory H

Get full text

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease by Shah, Niketa C., Bhoopatiraju, Sweta, Abraham, Allistair, Anderson, Eric, Andreansky, Martin, Bhatia, Monica, Chaudhury, Sonali, Cuvelier, Geoff D.E., Godder, Kamar, Grimley, Michael, Hale, Gregory, Kamani, Naynesh, Jacobsohn, David, Ngwube, Alexander, Gilman, Andrew L., Skiles, Jodi, Yu, Lolie C., Shenoy, Shalini

“…Granulocyte colony-stimulating factor (G-CSF) used after hematopoietic stem cell transplantation (HSCT) can enhance neutrophil recovery in patients rendered…”
Get full text

Randomized Trial of Hydroxychloroquine for Newly Diagnosed Chronic Graft-versus-Host Disease in Children: A Children’s Oncology Group Study by Gilman, Andrew L, Schultz, Kirk R, Goldman, Frederick D, Sale, George E, Krailo, Mark D, Chen, Zhengjia, Langholz, Bryan, Jacobsohn, David A, Chan, Ka-Wah, Ryan, Robin E, Kellick, Michael, Neudorf, Steven M, Godder, Kamar, Sandler, Eric S, Sahdev, Indira, Grupp, Stephan A, Sanders, Jean E, Wall, Donna A

“…The Children’s Oncology Group conducted a multicenter Phase III trial for chronic graft-versus-host disease (cGVHD). The double-blind, placebo-controlled,…”
Get full text

Early and Late Extensive Chronic Graft-versus-Host Disease in Children Is Characterized by Different Th1/Th2 Cytokine Profiles: Findings of the Children's Oncology Group Study ASCT0031 by Rozmus, Jacob, Schultz, Kirk R, Wynne, Kristin, Kariminia, Amina, Satyanarayana, Preeti, Krailo, Mark, Grupp, Stephan A, Gilman, Andrew L, Goldman, Frederick D

“…Numerous mechanisms underlie chronic graft-versus-host disease (cGVHD), including skewing of Th1/Th2 cytokine expression. There are biological differences…”
Get full text

Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient by Yeo, Crystal J J, Gilman, Andrew L

“…Biallelic BRCA2 mutations occur in 2% of patients with Fanconi anemia and are associated with a high risk of acute leukemia at an early age and a poor…”
Get full text